Highlights and publications from Frontage’s experts

Mr. Nicholas Pimlett joins Frontage Laboratories, as Vice President of Alliance & Program Management.

Prior to joining Frontage, Nicholas has over 18 years of experience at SANOFI where he held multiple positions of increasing responsibilities.  He started his career in the lab as a Bioanalytical Scientist, after he obtained his MBA, he transitioned to Outsourcing Management to support R&D Projects across North America, Europe, and Asia.  This scientific and operational experience provided him with an opportunity to serve as the Chief of Staff for the Global Preclinical Dept. and the NA R&D Hub.  He then transitioned to a Compliance and Business Operations role in the US before expanding to oversee a global Medical Business Operation and Compliance Organization that managed Financial Regulations in 40+ countries and Compliance Regulations in 85 countries.  His most recent position was with TEMPUS LABS as the Associate Vice President of Alliance Management.

Frontage Holdings Announces 2020 Interim Results

Since March 2020, the number of COVID-19 cases continued to rise in the United States, which negatively affected the Group’s business. The global pandemic has limited the full capacity of the Group’s employees performing laboratory services and lowered its delivery efficiency. The Group has employed various mitigation measures focusing on the safety and well-being of its employees, customers and partners, and the continuity of its business operations to minimize the adverse impact of the pandemic. The Group’s facilities in the United States continue to operate at a reduced utilization rate.

Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Greater China.

Frontage is pleased to announce the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc. and President of Frontage Greater China. Dr. Qi has nearly 30 years of experience in research and development leadership and overseeing operations in the regulated pharmaceutical industry. In this role, Dr. Qi will be responsible for the overall leadership and strategic growth of Frontage Greater China operations.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

ANVISA Certification

Brazil’s Agencia Nacional de Vigilancia Sanitaria (ANVISA) approved Frontage Laboratories to conduct bioanalytical services to support bioequivalence studies. ANVISA certified that Frontage Laboratories meets the agency’s stringent biopharmaceutical safety guidelines allowing the company to conduct bioanalytical work on its clients drug products.  The certification will be valid until August 2022. and has been published on ANVISA website (www.anvisa.gov.br.) 

Frontage expands synthetic & medicinal chemistry and process research & development services by acquisition of ACME Bioscience

ACME provides discovery chemistry, medicinal chemistry, process chemistry research & development, and chemical manufacturing services for worldwide biopharmaceutical companies.  ACME has extensive experience in antiviral and anti-bacterial research, along with expertise in nucleotides, nucleosides, triphosphates pro-drugs, heterocycles, and boron containing compounds, and has partnered with many customers in developing new chemical entities.

Frontage Laboratories, Inc establishes a QWBA Center of Excellence (COE) in Exton PA

Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services, has established a Quantitative Whole‑Body Autoradiography (QWBA) Center of Excellence (COE) at our Exton PA facility.